Siemens Healthineers: The Buyback Buffer Between a Slashed Outlook and a 2027 Breakup

Shares rise 13% above 200-day average, but Q3 guidance cut and diagnostics weakness temper optimism ahead of Siemens spin-off.

The rebound in Siemens Healthineers shares has been steady enough to look convincing — until you peel back the quarterly numbers underneath it. The stock has climbed 13 percent over the past 30 trading days, closing Tuesday at 39.55 euros after a 1.8 percent daily gain, and now sits roughly 1.1 percent above its 200-day moving average of 39.11 euros. That technical milestone, crossed after weeks of sideways churning, is the kind of signal chart-watchers treat as a potential trend shift. But the company's own guidance tells a more cautious story.

The rally traces back to late July, when the medical technology group published its fiscal third-quarter results. Revenue rose 2.8 percent to 5.76 billion euros, while net profit jumped 20 percent to 676 million euros — a figure flattered by US tariff refunds rather than operational momentum. Adjusted earnings per share came in at 0.70 euros, up from 0.49 euros a year earlier. The market's response, however, was muted, and for good reason: management simultaneously trimmed its full-year comparable growth forecast from 4.5 to 5.0 percent down to 3.5 to 4.0 percent, citing weakness in the diagnostics division.

That cut is the crux of the current debate. The diagnostics segment, which dragged the outlook lower, also missed expectations in imaging — UBS pegged organic growth there at 2.3 percent against a consensus of 5.4 percent. The bank called the overall print "unschön" (unattractive) and reaffirmed a Neutral rating with a 38-euro price target on August 3. Deutsche Bank took a slightly more constructive line on Tuesday, nudging its target from 38 to 39 euros while keeping a Hold rating, describing the quarter as "mixed" and flagging both the diagnostics revenue miss and cost-related caution, alongside Middle East uncertainties.

Against that fundamental softness, the company has been leaning on shareholder returns to steady the ship. A buyback program launched June 1 has now accumulated 2,824,371 shares, including 50,000 repurchased between August 10 and 16, according to a mandatory disclosure. The program is sized at up to 230 million euros and runs until January 29, 2027. Management also raised the dividend to 1.00 euro per share for fiscal 2025, approved back in February, and is rolling out a new strategic phase dubbed "Elevating Health Globally."

The buyback cadence signals internal confidence in the valuation, but the structural story is arguably bigger. The planned spin-off from parent Siemens AG is taking concrete shape. Siemens CFO Ralf Thomas confirmed in early August that outstanding tax questions with the authorities have been resolved, keeping the timeline intact. Under the roadmap reported in the spring, Siemens shareholders will vote in February 2027 on a direct distribution of 30 percent of the Healthineers stake, which would cut Siemens' holding from 67 percent to below 40 percent — reducing the medtech arm to a pure financial investment.

That prospect has weighed on the stock's multiple, a point Berenberg's Sam England made in early July when he slashed his price target from 54 to 39 euros and downgraded to Hold. He cited the spin-off uncertainty alongside currency headwinds, tariffs, inflation, a weak Chinese market, and the struggling diagnostics business as persistent drags.

The share price still sits 21 percent below its 52-week high of 49.78 euros from late October, and the year-to-date decline stands at 12 percent, with a 17 percent drop over twelve months. The recovery from the May low of 32.84 euros amounts to about 21 percent — a meaningful bounce, but one that has yet to be tested against fresh operational data. With annualized volatility of 31 percent over the past month, the market is clearly pricing in a wide range of outcomes.

The immediate question is whether the technical support holds. As long as the stock stays above the 200-day average, the recent advance retains its foundation. A break below that level would likely be read as confirmation that the diagnostics and imaging problems are more than a temporary blip — and that the buyback and dividend signals are no substitute for organic growth. The next catalysts are the further detailing of the spin-off plans and the coming quarterly reports, which will determine whether the lowered 3.5 to 4.0 percent growth forecast holds as a floor or proves to be yet another step on a downward path.